ArticlePhysics and imaging in radiation oncology2026
Monte Carlo-based characterization of proton minibeam radiation therapy across clinically relevant beam parameters.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Proton minibeam radiotherapy (pMBRT) uses a 1D array of narrow beams to widen the therapeutic window of difficult-to-treat tumors. With the aim of identifying tumor locations that could benefit most from pMBRT, we evaluated how irradiation parameters shape 3D dose distributions. Materials and methods: Monte Carlo simulations were used to compute dose distributions in water for different proton energies, beam widths (bw Results: For shallow tumors (≤ 2 cm), 0.5 mm beams with ctc = 3bw kept normal-tissue widths < 1 mm with Bragg-peak-to-entrance dose ratio (BEDR) > 1. For intermediate and deep-seated tumors (8-20 cm), 1.0-1.5 mm beams with ctc = 4-5bw kept normal-tissue widths < 7 mm with peak-to-valley dose ratio (PVDR) > 3 and achieved lateral dose homogeneity in the target. For very deep-seated tumors (> 20 cm), 2 mm beams with ctc = 4bw maintained normal-tissue widths < 10 mm with PVDR > 3 at the cost of BEDR ∼ 0.5. Conclusion: pMBRT may offer advantages over conventional proton therapy and GRID therapy for treating shallow and deep-seated tumors. For very deep-seated tumors (> 20 cm), feasibility will depend on tumor size and proximity of organs at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.